Amifampridine

Chemical formula: Câ‚…H₇N₃  Molecular mass: 109.132 g/mol  PubChem compound: 5918

Therapeutic indications

Amifampridine is indicated for:

Lambert-Eaton myasthenic syndrome (LEMS)

Population group: only adults (18 years old or older)

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Amifampridine is contraindicated in the following cases:

Epilepsy

Epilepsy

Uncontrolled asthma

Airway hyperreactivity

Sultopride

Sultopride

Medicinal products that can prolong QTc interval

Drugs prolonging QT interval

Congenital QT syndrome

Congenital long QT syndrome

Medicinal products with a narrow therapeutic window

Narrow Therapeutic Index Drugs (NTI)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: FIRDAPSE Tablet
Summary of Product Characteristics (SPC) 2022: FIRDAPSE Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈